- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07945431
A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction
A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction
This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Todd Bertoch, MD
- Numéro de téléphone: 928 830 7354
- E-mail: t.bertoch@cenexel.com
Sauvegarde des contacts de l'étude
- Nom: CenExel JBR Recruiting
Lieux d'étude
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84107
- CenExel JBR Clinical Research
-
Contact:
- Todd M Burtoch, MD
- Numéro de téléphone: 2303 (801) 261-2000
- E-mail: t.bertoch@cenexel.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Is male or female ≥ 18 and ≤ 50 years of age.
- Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
- Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
- Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
- Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
- Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
- Able to provide written informed consent.
- Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)
Exclusion Criteria:
- Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
- History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
- Complications from tooth extraction resulting in a "severe" surgical trauma rating.
- Dental surgery within 60 days prior to Day 1.
- Positive urine drug screen or alcohol breathalyzer test.
- Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
- Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
- Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ≥ 4 weeks prior to Screening.
- History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
- Difficulty swallowing oral medication.
- Investigational drug exposure within 30 days or 5 half-lives.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: SRP-001
SRP-001 Single Oral Suspension dose of 2,000 mg |
SRP-001 Oral Suspension |
|
Comparateur placebo: Matching Placebo for SRP-001
Matching Placebo for SRP-001 Oral Suspension |
Matching Placebo for SRP-001 Oral Suspension
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Délai: 0 to 6 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo. |
0 to 6 hours post-dose
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Délai: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse) |
0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
|
Sum of pain relief (TOTPAR)
Délai: O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose. |
O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
|
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Délai: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Délai: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to first use of rescue medication
Délai: 0 - 6, 0-8, 0-24 hours post dose.
|
Rescue medication time for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Total rescue medication consumption
Délai: 0 - 6, 0-8, 0-24 hours post dose.
|
Total rescue medication consumption for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication |
Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
|
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Délai: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
Pain intensity difference (PID) Scale is -10 to 10 (higher is better) |
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
|
Patient's global evaluation of study drug using a 5 point categorical scale
Délai: Up to 6 hours post dose
|
Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent |
Up to 6 hours post dose
|
|
Number of participants with clinically significant abnormalities in laboratory abnormalities
Délai: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
Number of participants with laboratory values judged clinically significant by the investigator in the following panels: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential) |
Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
|
Maximum Observed Plasma Concentration (CMax) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Time to maximum observed plasma concentration (Tmax) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
Délai: Pre-dose through 12 hours post-dose
|
AUC0-12 of SRP-001 following a single 2,000mg oral dose. |
Pre-dose through 12 hours post-dose
|
|
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-t of SRP001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-inf of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Terminal elimination half life (t 1/2) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
t 1/2 of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent oral clearance (CL/F) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CL/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Vz/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Délai: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Pain relief difference (PR) |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to first perceptible relief and time to confirmed perceptible pain relief
Délai: 0-4.5 hours post dose
|
TPPR and TCPR via stopwatch 1 |
0-4.5 hours post dose
|
|
Time to meaningful relief
Délai: 0-4.5 hours post dose
|
TMPR via Stopwatch 2 |
0-4.5 hours post dose
|
|
Time to complete pain relief
Délai: 0 to 8 hours post-dose
|
TCOMPR, NPRS = 0 |
0 to 8 hours post-dose
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Todd M Bertoch, MD, CenExel JBR Clinical Research
Publications et liens utiles
Publications générales
- Coderch C, Bazan HA, Bazan NG, Surjyadipta B, Alvarez-Builla J, de Pascual-Teresa B. Computational Insights into the Structural Basis for Reduced Hepatotoxicity of Novel Nonopioid Analgesics. ChemMedChem. 2025 Nov 18;20(22):e202500639. doi: 10.1002/cmdc.202500639. Epub 2025 Oct 21.
- Olson AC, Afyusisye F, Egger J, Noyd D, Likonda B, Masalu N, Suneja G, Chao N, Zullig LL, Schroeder K. Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases. Cancer Epidemiol. 2020 Aug;67:101772. doi: 10.1016/j.canep.2020.101772. Epub 2020 Jul 10.
- Bazan HA, Giles BL, Bhattacharjee S, Edwards S, Bazan NG. A non-toxic analgesic elicits cell-specific genomic and epigenomic modulation by targeting the PAG brain region. Neurobiol Pain. 2025 Jul 20;18:100192. doi: 10.1016/j.ynpai.2025.100192. eCollection 2025 Jul-Dec.
- Frelinger AL 3rd, Haynes RL, Goldstein RD, Berny-Lang MA, Gerrits AJ, Riehs M, Haas EA, Paunovic B, Mena OJ, Campman SC, Milne GL, Sleeper LA, Kinney HC, Michelson AD. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 May 15;14(1):11092. doi: 10.1038/s41598-024-61949-9.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SRP-001-002
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .